Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

DPP-IVi, Topics

October 04, 2018

CARMELINA Neutral on CV and Renal Outcomes; No Increased hHF Risk

Here is a brief preview of this blast: BI/Lilly presented data from CARMELINA, the Tradjenta CV and renal outcomes study (press release). Unsurprisingly, the trial failed to demonstrate superiority for either CV or renal composite endpoints. Of note, there was no increased risk of hospitalization for heart failure with Tradjenta. Below, FENIX provides thoughts on the neutral CARMELINA result.